IPO Year: 2023
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|
SC 13G/A - CytoMed Therapeutics Ltd (0001873093) (Subject)
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has, through its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) ("CISB"), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources. The price consideration includes a cord blo
6-K/A - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K/A - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
20-F - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement ("RCA") with Sengkang General Hospital Pte Ltd ("SKH"), a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells ("UC-MSCs") to treat ca
Gainers KalVista Pharma (NASDAQ:KALV) stock moved upwards by 11.0% to $15.99 during Wednesday's after-market session. The market value of their outstanding shares is at $552.5 million. Anitra (AMEX:AZTR) stock increased by 9.25% to $0.25. The company's market cap stands at $3.0 million. CytoMed Therapeutics (NASDAQ:GDTC) stock rose 7.5% to $2.58. The market value of their outstanding shares is at $29.7 million. Vaccinex (NASDAQ:VCNX) stock rose 7.12% to $0.85. The market value of their outstanding shares is at $10.6 million. Universe Pharmaceuticals (NASDAQ:UPC) shares moved upwards by 6.66% to $1.68. The company's market cap stands at $6.1 million. Cidara Therapeutics (NASDAQ:CDTX) st
Gainers NanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stock rose 21.81% to $1.34. OKYO Pharma (NASDAQ:OKYO) stock increased by 21.32% to $1.74. The company's market cap stands at $57.6 million. Corvus Pharma (NASDAQ:CRVS) shares moved upwards by 20.5% to $2.41. The market value of their outstanding shares is at $118.1 million. CytoMed Therapeutics (NASDAQ:GDTC) stock rose 14.28% to $2.56. The market value of their outstanding shares is at $29.5 million. Ontrak (NASDAQ:OTRK) stock increased by 11.76% to $0.19. The company's market cap st
Shares of The Container Store Group, Inc. (NYSE:TCS) shares fell sharply during Wednesday’s session following weak quarterly results. Container Store Group posted adjusted loss of 8 cents per share, compared to market expectations for a loss of 5 cents per share. The company’s quarterly sales came in at $214.90 million versus estimates of $220.72 million. Container Store Group shares dipped 22.7% to $1.3150 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MicroCloud Hologram Inc. (NASDAQ:HOLO) shares jumped 400% to $7.51. The company announced it planned to join the Communications Industry Association. HOLO intends to join the Communications Indust
Gainers ThermoGenesis Holdings (NASDAQ:THMO) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. The market value of their outstanding shares is at $2.7 million. Femasys (NASDAQ:FEMY) shares increased by 21.51% to $1.06. The company's market cap stands at $22.9 million. PepGen (NASDAQ:PEPG) stock rose 13.77% to $12.1. The company's market cap stands at $288.1 million. Abeona Therapeutics (NASDAQ:ABEO) shares rose 13.48% to $4.88. The company's market cap stands at $120.8 million. FibroGen (NASDAQ:FGEN) shares increased by 12.87% to $2.16. The market value of their outstanding shares is at $212.0 million. Perspective Therapeutics (AMEX:CATX) stock increased by 12.7
MIAMI, Aug. 21, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteM
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Info
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485
SINGAPORE, July 17, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has, through its wholly owned subsidiary, IPSC Depository Sdn Bhd acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation) ("CISB"), a Malaysian cord blood bank for a cash consideration of approximately RM 2.3 million or US$ 490,000 to be funded from internal cash resources. The price consideration includes a cord blo
MIAMI, July 16, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73rd Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Sponsors:QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions(844) 485-8200Sales@QuoteMedi
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced that it has entered into a research collaboration agreement with Sengkang General Hospital Pte Ltd., a public hospital in Singapore and a member of the SingHealth Group. The two entities aim to establish a proof-of-concept for the use of an injectable cartilage regeneration therapy developed from donor-sourced umbilical cord-derived mesenchymal stem cells (UC-MSCs). This inj
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program ("Program") to isolate and cryo-store peripheral blood mononuclear cells ("PBMCs") for and as a reward to loyal shareholders of CytoMed on a complimentary basis. This Program is in line with the Company's strategy to build up a private bank of PBMC donors t
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement ("RCA") with Sengkang General Hospital Pte Ltd ("SKH"), a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derive
SINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced today that the Intellectual Property Corporation of Malaysia has granted a patent for its chimeric antigen receptor gamma delta T cell ("CAR-γδ T cell") technology, which targets solid and hematological tumors. The patent titled "Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same" (Patent number: MY-200528-A) covers technologies for the clinical
SINGAPORE, Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學. The HOA forms a collaborative effor